{"name":"Lyra Therapeutics","slug":"lyra","ticker":"LYRA","exchange":"NASDAQ","domain":"lyratx.com","description":"Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 20","hq":"Watertown, MA","founded":0,"employees":"27","ceo":"Todd Bazemore","sector":"ENT / Specialty Pharma","stockPrice":0.75,"stockChange":0.03,"stockChangePercent":4.17,"marketCap":"$1M","metrics":{"revenue":1534000,"revenueGrowth":-96.7,"grossMargin":-152.8,"rdSpend":43766000,"netIncome":-93435000,"cash":15893000,"dividendYield":0,"peRatio":-0.8,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Lyra Therapeutics reported its fourth quarter and full year 2023 financial results, with a net loss of $24.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Lyra Therapeutics Announces Collaboration with University of California, San Francisco","summary":"Lyra Therapeutics announced a collaboration with the University of California, San Francisco to develop new treatments for ENT disorders.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"trial","headline":"Lyra Therapeutics Announces Positive Topline Results from Phase 2 Clinical Trial of LAYR","summary":"Lyra Therapeutics announced positive topline results from its Phase 2 clinical trial of LAYR, its lead product candidate for chronic rhinitis.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE41Z2R0QW05Rk1RRWNjcDFYSjBwaFhZN3E4djVQTVhiSk5GUkdhcjJWQVdoNUY3VzlybDhET2dqYmNhUUZERm1LcjI0aURCZjI5Y3k3UGRmazBPaVJEc3Iw?oc=5","date":"2026-03-16","type":"pipeline","source":"ChartMill","summary":"LYRA Stock Price, Quote & Chart | LYRA THERAPEUTICS INC (NASDAQ:LYRA) - ChartMill","headline":"LYRA Stock Price, Quote & Chart | LYRA THERAPEUTICS INC (NASDAQ:LYRA)","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNNkd6WGtfOV9MMGRtX0pPUnpYTlZKRmJuakR5YUZaSVpDbFdXZ1VibEF3cHJoRzZqUlNfU0JJbVdkVWYwMXQ0dnlGQVdLVE85MVpQTWRRRWFFTnZ3a1RMYkV5UFZGc3dWX01QNkpXTGVvNFVNSU1HWE1FRXlQaGFvUFJPYUZvZE1EVkdzRGEyNGs0UTBXRnk0NE42T2JuNVBOUUQ4dmFDVHY3NnVMZF82Qk9teGpTVUZsNEZQb19pZXE5Zw?oc=5","date":"2026-02-11","type":"pipeline","source":"AD HOC NEWS","summary":"Lyra Therapeutics Faces Nasdaq Delisting Battle After Clinical Setback - AD HOC NEWS","headline":"Lyra Therapeutics Faces Nasdaq Delisting Battle After Clinical Setback","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPVDc0ZHBpREVFY1VVZHoyaFZLTnhNNDFnZVNiTWNmUl9ZTVJ2Tno2bjJZalZUQ0hwYk1vSkRNQy1TcmhVQzZNY0l5RXM2OTZMdE04aFFCVFRBNUlCNFhFNzJmN0pGX1ptSnA1dFNCOE1UemJIREozTE5PV0I3alRoSnRLOWVfdUtxSmVram44aktuM2lKX0h3MVdHcw?oc=5","date":"2026-01-13","type":"pipeline","source":"Fierce Biotech","summary":"Lyra ditches sole rhinosinusitis asset, lays off all employees - Fierce Biotech","headline":"Lyra ditches sole rhinosinusitis asset, lays off all employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOUTdBdXN4WTlBQUVUd3lrOXhrM3c0aGxXTnh2Z0JtdmtQLU1BZy1rUzY1Qm5NcjBDWWFTMlVRUVQxRnotMWRxRGJKV0tTQ2dGejJPVFVfWkE1Nm5vYldLZnBXbkpjZ1RxR0FqRnViZGpDRlhkTXBZLXpjQVVXZ0JFSWZ2cVNMLXVnSzV1RVhwMTNyWU96akszTkI5QTdKWVk0XzNtZWNQd3daSkQwb3I2ZmpJVzhtQQ?oc=5","date":"2026-01-12","type":"pipeline","source":"globenewswire.com","summary":"Lyra Therapeutics Provides Corporate Update - globenewswire.com","headline":"Lyra Therapeutics Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE94TDFPbkJFT2JMYmpPRWRnN25WVG5pX0RuaFZyV3hleTlXV1U0LWlNNVlmRlNtTVBUc1MxdmVLUUZxT0Z0UEpPbUl2Zl9HSjFtcC1z?oc=5","date":"2026-01-12","type":"pipeline","source":"firstwordpharma.com","summary":"Biopharma bites: Teva, Kinaset pull in funds, Camzyos wins in teens, plus contrasting fortunes for Lynk, Lyra - firstwordpharma.com","headline":"Biopharma bites: Teva, Kinaset pull in funds, Camzyos wins in teens, plus contrasting fortunes for Lynk, Lyra","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNVUhxNDl0Um1XRHVMekdNNGRiTXpsZFJJYXVBWUI3WkVpWEFoTDZwZGVtcktTTXRVdmN4eTU2SXpzRmI0NEdyMWZveGRLSXVKRUlFOU5kdUwxSmlJNmp0NHozXzdOM3kyMkRlVjRGQi0yclJ0S2M1RW1zOE0xVmVwNHZfQlMtS0U?oc=5","date":"2025-11-12","type":"earnings","source":"Yahoo Finance","summary":"Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance","headline":"Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-15","type":"earnings","source":"simplywall.st","summary":"Lyra Therapeutics First Half 2025 Earnings: In Line With Expectations - simplywall.st","headline":"Lyra Therapeutics First Half 2025 Earnings: In Line With Expectations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQb2VyOWUtSWJRU3U1TzAxVVg4TGQzYlg4SlZCTjAyal80MkIyTEN1SXhLSXJSUnNtQzMzMl9LWkZ1NjVCWVBqaWlXVFdQbVVDWUpJUHg0QmhLOTBQd3FuTVJXRXA3S2RuNk1jTHFmTlIyNGJCUkx1SndVRDAyRGtNRDBqd2JESWNtY1Y0VnZVVFJJLWU3TFgxUEdMVmZ1bWJ4Z0tpWXF1cUl5NGZXTFZ5Mw?oc=5","date":"2025-06-16","type":"regulatory","source":"Seeking Alpha","summary":"Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha","headline":"Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPcVV0b01UUnN4WEl3TnM5aWxtTjRYaTl1X2Z6d0lveWVSNXRRZTZNUTJGd2JRYzByRFlyLXJ1UzM5bGlob2JrMnZaRXozVXExR1ppeXZMMVU2Y3pibHJFUEQxME5CZnJZcVgxbjdnck9xWXNuUTRFNFR2ZUNIbGR2dFVlRS1rTkFBelR2VTBIbDN2aW1IWEw4ejdLOFVrckcxQjc5OFpTdEpVUQ?oc=5","date":"2025-06-04","type":"trial","source":"Pharmacy Times","summary":"Study: LYR-210 Shows Promise in Chronic Rhinosinusitis With Nasal Polyps - Pharmacy Times","headline":"Study: LYR-210 Shows Promise in Chronic Rhinosinusitis With Nasal Polyps","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1OQmpyUGozajhRaks0ZHZhN29WRFZQeE40UVBNbHNiWlNwVUZLUEdfMzNkeTZnRjdvQl9aUU5oOHNwdkxnc3dXMnE5LThqNU5jdWktdGFWNHlCM2EwVE9Od0JoWldHQQ?oc=5","date":"2024-05-11","type":"pipeline","source":"MarketBeat","summary":"Lyra Therapeutics (LYRA) Stock Forecast and Price Target 2026 $LYRA - MarketBeat","headline":"Lyra Therapeutics (LYRA) Stock Forecast and Price Target 2026 $LYRA","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Intersect ENT","Entasis Therapeutics","Auris Medical Holding"],"therapeuticFocus":["Ear, Nose, and Throat (ENT) Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":1534000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":1534000,"period":"2024-12-31"},{"value":1558000,"period":"2023-12-31"},{"value":1558000,"period":"2023-12-31"},{"value":1363000,"period":"2022-12-31"},{"value":1363000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":43766000,"rdSpendHistory":[{"period":"2025-12-31","value":18411000},{"period":"2024-12-31","value":43766000},{"period":"2023-12-31","value":48029000},{"period":"2022-12-31","value":38797000}],"sgaSpend":11540000,"operatingIncome":-29553000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-29553000},{"period":"2024-12-31","value":-60733000},{"period":"2023-12-31","value":-65528000},{"period":"2022-12-31","value":-54990000}],"netIncome":-93435000,"netIncomeHistory":[{"period":"2025-12-31","value":-28919000},{"period":"2024-12-31","value":-93435000},{"period":"2023-12-31","value":-62680000},{"period":"2022-12-31","value":-55278000}],"eps":-71.75,"epsHistory":[{"period":"2024-12-31","value":-71.75},{"period":"2023-12-31","value":-63},{"period":"2022-12-31","value":-91.5},{"period":"2021-12-31","value":-167.5}],"cash":15893000,"cashHistory":[{"period":"2025-12-31","value":15893000},{"period":"2024-12-31","value":40577000},{"period":"2023-12-31","value":22353000},{"period":"2022-12-31","value":32550000}],"totalAssets":66346000,"totalLiabilities":46825000,"totalDebt":30259000,"equity":-10717000,"operatingCashflow":-28859000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-28859000},{"period":"2024-12-31","value":-70011000},{"period":"2023-12-31","value":-63304000},{"period":"2022-12-31","value":-43385000}],"capex":-116000,"capexHistory":[{"period":"2025-12-31","value":-116000},{"period":"2024-12-31","value":-2338000},{"period":"2023-12-31","value":-1047000},{"period":"2022-12-31","value":-164000}],"freeCashflow":-28975000,"dividendsPaid":null,"buybacks":null,"employees":27,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":2540000,"ebit":-6911000,"ebitda":-6811000,"period":"2025-12-31","revenue":7000,"epsBasic":null,"netIncome":-6951000,"rdExpense":4378000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-6911000},{"sga":2236000,"ebit":-6258000,"ebitda":-6154000,"period":"2025-09-30","revenue":25000,"epsBasic":-3.38,"netIncome":-5984000,"rdExpense":4047000,"epsDiluted":-3.38,"grossProfit":null,"operatingIncome":-6258000},{"sga":3501000,"ebit":-8428000,"ebitda":-8301000,"period":"2025-06-30","revenue":183000,"epsBasic":-5.51,"netIncome":-7437000,"rdExpense":5110000,"epsDiluted":-5.51,"grossProfit":null,"operatingIncome":-8428000},{"sga":3263000,"ebit":-7956000,"ebitda":-7828000,"period":"2025-03-31","revenue":183000,"epsBasic":-6.5,"netIncome":-8547000,"rdExpense":4876000,"epsDiluted":-6.5,"grossProfit":null,"operatingIncome":-7956000},{"sga":3613000,"ebit":-9766000,"ebitda":-9615000,"period":"2024-12-31","revenue":209000,"epsBasic":null,"netIncome":-10979000,"rdExpense":6362000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-9766000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-9.07,"netIncome":null,"rdExpense":null,"epsDiluted":-9.07,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.75,"previousClose":0.72,"fiftyTwoWeekHigh":37.5,"fiftyTwoWeekLow":0.31,"fiftyTwoWeekRange":"0.31 - 37.5","fiftyDayAverage":0.71,"twoHundredDayAverage":3.57,"beta":0.69,"enterpriseValue":15697162,"forwardPE":-0.8,"priceToBook":-0.12,"priceToSales":3.34,"enterpriseToRevenue":39.44,"enterpriseToEbitda":-0.54,"pegRatio":0,"ebitda":-29094000,"ebitdaMargin":0,"freeCashflow":-17529624,"operatingCashflow":-28859000,"totalDebt":30259000,"debtToEquity":0,"currentRatio":1.71,"returnOnAssets":-36.1,"returnOnEquity":-6595,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.6,"institutionHeldPercent":19.9,"sharesOutstanding":1774882,"floatShares":395692,"sharesShort":16533,"shortRatio":0.35,"shortPercentOfFloat":0.9,"epsTrailing":-18.62,"epsForward":-0.99,"revenuePerShare":0.26,"bookValue":-6.04,"officers":[{"age":57,"name":"Dr. Carmichael S. Roberts Jr., M.B.A., Ph.D.","title":"Co-Founder"},{"age":52,"name":"Mr. Ronan P. O'Brien J.D.","title":"Chief Legal Officer"},{"age":null,"name":"Ms. Vineeta  Belanger Ph.D.","title":"Senior Vice President of Clinical Affairs"},{"age":null,"name":"Ms. Allison  Nance","title":"Senior Vice President of Regulatory Affairs"},{"age":68,"name":"Dr. Elazer R. Edelman FACC, M.D., Ph.D.","title":"VP of Finance & Risk"}],"industry":"Biotechnology","irWebsite":"","website":"https://lyratherapeutics.com","phone":"617 393 4600"}}